Leerink’s Risinger on Eli Lilly downgrade: Triggered by disappointing obesity pill resultsAugust 7, 2025
Leerink’s Risinger on Eli Lilly downgrade: Triggered by disappointing obesity pill resultsAugust 7, 2025
Share Facebook Twitter LinkedIn Pinterest Email Asad Haider, Goldman Sachs analyst, joins ‘Money Movers’ to discuss Eli Lilly tumbling on trial results and his outlook for the stock.